Year: 2021
Type: article
Abstract: Sodium-glucose co-transporter 2 inhibitor (SGLT2-i) is an oral hypoglycemic drug with a proven advantage regarding weight reduction effects in type 2 diabetes patients. By its main mechanism, it increases urinary glucose loss which can cause negative energy balance hence weight loss. Other mechanisms that might play roles in its weight-losing effect include loss of extracellular fluid by transient increase of urinary output, increase body lipid oxidation, and increase metabolism by inducing the fat-browning(burning?) process. The magnitude of SGLT2-i-induced weight loss usually ranges from 1-3 kg, which is commonly observed within the first 6 months of prescription. Then the rate of weight loss gradually declines afterward to reach a plateau after 6 months to 1 year. Fat mass loss contributes a major proportion in body weight loss whereas muscle and bone mass losses are minute. Adherence to diet control, SGLT2-i dosage increment, or a combination with GLP-1 RA should be considered to achieve greater weight loss effect. Currently, SGLT2-i has not been approved as an anti-obesity drug in patients without type 2 diabetes mellitus.
Source: Thai JPEN วารสารโภชนบำบัด
Author: Rattanachaiwong, Sornwichate
Institution: Khon Kaen University
Language: Thai
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7220504500
